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in breast cancer cells
David R. CROUCHER*1, Darren N. SAUNDERS†‡, Gillian E. STILLFRIED* and Marie RANSON*2
*School of Biological Sciences, University of Wollongong, NSW 2522, Australia, †Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia, and
‡Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC,
Canada V5Z 1L3
PAI-1 and PAI-2 (plasminogen-activator inibitor types 1 and 2) are
inhibitors of cell surface uPA (urokinase plasminogen activator).
However, tumour expression of PAI-1 and PAI-2 correlates with
poor compared with good patient prognosis in breast cancer
respectively. This biological divergence may be related to addi-
tional functional roles of PAI-1. For example, the inhibition of
uPA by PAI-1 reveals a cryptic high-affinity site within the PAI-
1 moiety for the VLDLr (very-low-density-lipoprotein receptor),
which sustains cell signalling events initiated by binding of uPA to
its receptor. These interactions and subsequent signalling events
promote proliferation of breast cancer cells. Biochemical and
structural analyses show that, unlike PAI-1, the PAI-2 moiety
of uPA–PAI-2 does not contain a high-affinity-binding site for
VLDLr, although uPA–PAI-2 is still efficiently endocytosed via
this receptor in breast cancer cells. Furthermore, global protein
tyrosine phosphorylation events were not sustained by uPA–PAI-
2 and cell proliferation was not affected. We thus propose a
structurally based mechanism for these differences between PAI-1
and PAI-2 and suggest that PAI-2 is able to inhibit and clear uPA
activity without initiating mitogenic signalling events through
VLDLr.
Key words: plasminogen-activator inhibitor type 1 (PAI-1),
plasminogen-activator inhibitor type 2 (PAI-2), serpin (serine
protease inhibitor), urokinase plasminogen activator (uPA),
very-low-density lipoprotein receptor (VLDLr).
INTRODUCTION
uPA (urokinase plasminogen activator) plays an important role
in many physiological processes including metastasis, wound
healing and angiogenesis, through the pericellular activation of
plasminogen and degradation of the extracellular matrix [1].
The deregulation of uPA expression associated with metastatic
cancer increases plasmin activity, catalysing extracellular matrix
degradation and promoting migration [2]. Importantly, uPA can
also promote metastasis through protease-independent mechan-
isms [3]. For example, binding of uPA to its cell-surface receptor,
uPAR, often initiates mitogenic signalling responses [4]. As uPAR
is not a transmembrane receptor, these and other potential cellular
responses are facilitated by interactions with integrins [5] and
associated co-receptors, including the EGFR (epidermal growth
factor receptor) [6] and endocytosis receptors of the LDLR (low-
density lipoprotein receptor) family [7].
The key physiological inhibitors of uPA, PAI-1 and PAI-2
(plasminogen-activator inhibitor types 1 and 2), belong to the
serpin (serine protease inhibitor) superfamily (also known as
SerpinE1 and SerpinB2 respectively). Despite only 24% amino
acid sequence identity and their classification into different serpin
classes, PAI-1 and PAI-2 fold into a well-conserved tertiary
structure among serpins, which consists of three β-sheets, 8–9 α-
helices and an RCL (reactive centre loop) containing the protease
recognition site [8]. A structural feature unique to PAI-2 is an
extended sequence of 33 amino acids between α-helices C and D
known as the C–D loop (Ala65–Glu96) [9]. In a similar manner to
other inhibitory serpins, PAI-1 and PAI-2 interact with their target
protease through the RCL which ultimately leads to the formation
of SDS-stable, equimolar covalent complexes in which the serpin
adopts a more thermodynamically stable, relaxed conformation
[8].
Although both PAI-1 and PAI-2 are efficient inhibitors of
soluble or receptor-bound uPA [10,11], their apparent role(s)
in breast cancer invasion and metastasis appear somewhat
paradoxical. Clinical studies show that uPA–PAI-1 co-expression
has level one evidence as a prognostic marker of progression in
early breast cancer [12,13] and may have prognostic significance
in ovarian, endometrial, bladder and other cancers [14]. In vitro
studies have shown that uPA and PAI-1 are necessary for lung
carcinoma cell invasion through Matrigel [15] and that PAI-1
deficiency inhibited invasion of transplanted malignant keratino-
cytes [16]. In contrast, high PAI-2 expression in breast carcinomas
that also express uPA is correlated with prolonged relapse-
free survival, whereas low levels of PAI-2 are associated with
metastasis from various carcinomas [9,14,17]. Furthermore, a
number of observations have shown that PAI-2 reduces tumour
growth, invasion and metastasis using in vitro and in vivo models
via inactivation of cell-surface uPA [9].
Both PAI-1 and PAI-2 can be internalized into cells through
interactions with endocytosis receptors of the LDLR family, such
as LRP (low-density lipoprotein receptor-related protein) and
VLDLr (very-low-density lipoprotein receptor) [18–21]. Upon
PAI-1/2 inhibition of uPAR-bound uPA, a covalent complex is
formed with increased affinity for these receptors, resulting in an
enhanced rate of uPA–serpin complex endocytosis [19,22]. In the
case of PAI-1, specific arginine and lysine residues within (Arg76
and Lys80) and adjacent (Lys88, Arg118 and Lys122) to the helix D
of PAI-1 have been shown to form part of a cryptic high-affinity
binding site for LRP and VLDLr, exposed by complex formation
with uPA [23,24]. The interaction of uPA–PAI-1 with LDLRs
Abbreviations used: ERK, extracellular-signal-regulated kinase; LDLR, low-density lipoprotein receptor; LRP, low-density lipoprotein receptor-related
protein; PAI, plasminogen-activator inhibitor; RAP, receptor-associated protein; RCL, reactive centre loop; serpin, serine protease inhibitor; SPR, surface
plasmon resonance; uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor; VLDLr, very-low-density lipoprotein receptor.
1 Present address: Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia
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can indirectly affect signalling activity by regulating levels of
uPA/uPAR on the cell surface [25] and also directly transmit
signals through receptor cytoplasmic domains [24,26–28]. PAI-1
is also capable of stimulating cell migration independently of uPA,
tPA (tissue plasminogen activator) and vitronectin. For example, a
direct interaction between PAI-1 and LRP activates the Jak/STAT
pathway, resulting in actin filament polarization, translocation of
activated STAT1 into the nucleus and increased cell migration
[29].
We have previously shown that specific and efficient internal-
ization of PAI-2 is dependent on forming a complex with cell
surface uPAR-bound uPA [10]. However, we also found that PAI-
2, unlike PAI-1, cannot bind directly to LRP and that uPAR/uPA–
PAI-2 endocytosis is mediated predominantly by binding sites
within the uPA moiety of the complex [19]. In the present study,
we not only show that this also applies to VLDLr but highlight
novel differences in VLDLr binding mechanisms between uPA–




Recombinant human PAI-2 (47 kDa form) was provided by PAI-
2 Pty Ltd. Human HMW (high-molecular mass) uPA, anti-
uPAR polyclonal antibody (#399r) and Spectrozyme PL substrate
were from American Diagnostica. Anti-VLDLr (H-95) poly-
clonal antibody was from Santa Cruz Biotechnology. Anti-
rabbit IgG-FITC was from Sigma–Aldrich. Glu-plasminogen was
purified from human plasma, as previously described [30]. Anti-
phosphotyrosine monoclonal antibody clone PY20 (#P11120)
was from BD Biosciences. The Alexa Fluor® 488 labelling kit
and Alexa Fluor® 488 polyclonal antibody were from Invitrogen.
Purified human RAP (receptor-associated protein), anti-LRP
polyclonal antibody and anti-VLDLr blocking monoclonal
antibodies (5F3 and 1H5, [31]) were a gift of Professor Dudley
Strickland (Center for Vascular and Inflammatory Diseases,
University of Maryland School of Medicine, MD, U.S.A.).
Recombinant human VLDLr ligand-binding region was a gift of
Professor Dieter Blaas (University of Vienna, Vienna, Austria).
Recombinant PAI-1 14-1b stable variant and PAI-1R76E mutant
on 14-1b backbone were provided by Professor Daniel Lawrence
(University of Michigan, Michigan, U.S.A.) [24].
Cell culture
The MCF-7 epithelial breast cancer cell line was used for all
experiments. Cells were grown, passaged and prepared for experi-
ments as previously described [10].
Analysis of cell-surface antigen expression and internalization by
flow cytometry
MCF-7 cells, grown to 80% confluency over a 48 h period,
were detached using PBS/EDTA (5 mM), washed with ice-cold
binding buffer (Phenol-Red-free Hanks buffered salt solution,
pH 7.4, containing 1 mM CaCl2, 1 mM MgCl2 and 0.1% BSA)
and centrifuged at 300 g at 4 ◦C. The cells were resuspended at 1 ×
106 cells/ml in ice-cold binding buffer containing primary poly-
clonal antibodies or irrelevant isotype control antibody (5 µg/ml)
and incubated for 45 min on ice. After three washes with ice-
cold binding buffer, the cells were incubated with goat anti-rabbit
IgG-FITC (1:50 dilution) for 45 min on ice. In all cases cell
surface fluorescence was analysed by dual-colour flow cytometry
as previously described [30].
Internalization assays using Alexa Fluor® 488 labelled PAI-2 or
uPA and Alexa Fluor® 488 polyclonal quenching antibody were
performed as previously described [19].
Preparation of uPA–serpin complexes
uPA–serpin complexes were prepared as previously described
[28]. Briefly, uPA and serpin (PAI-1 or PAI-2) were incubated
at a 1:1 molar ratio for 30 min at 37 ◦C. Complex formation was
monitored by SDS/PAGE and Western blotting for uncomplexed
uPA (results not shown). These analyses confirmed the complete
inactivation of uPA.
SPR (surface plasmon resonance) analysis
VLDLr was immobilized to a CM5 BIAcore chip according
to the manufacturer’s instructions. Briefly, the chip was activ-
ated using a 1:1 mixture of 0.2 M N-ethyl-N ′-(3-dimethylamino-
propyl)carbodi-imide and 0.05 M N-hydroxysuccimide. VLDLr
was coated to the chip at 40 µg/ml in 10 mM sodium acetate
(pH 3) to a level of ∼10000 response units. Unoccupied binding
sites were blocked using 1 M ethanolamine (pH 8.5). Ligands
were diluted into running buffer [10 mM Hepes (pH 7.4), 140 mM
NaCl, 1 mM CaCl2 and 0.05% Tween-20] before applying to the
BIAcore chip at 20 µl/min. Regeneration of the chip was achieved
using 100 mM H3PO4. For kinetic analysis, a blank cell was used
as the reference cell and data were analysed using BIAevaluation
software (Version 4).
Plasmin activity assay
MCF-7 cells were seeded in 96-well plates at 1 × 104 cells/well
and cultured for 48 h without change of medium. Cells were
washed and incubated in binding buffer containing purified human
uPA (5 nM) for 30 min on ice. Cells were subsequently washed
and incubated for 0, 1, 10 or 30 min at 37 ◦C in binding buffer
containing PAI-1 or PAI-2 (5 nM). Cells were then washed and
incubated with 0.5 µM human Glu-plasminogen for 10 min at
room temperature (25 ◦C). Plasmin activity was then measured
over 2 h at 37 ◦C using Spectrozyme PL substrate (0.4 mM final
concentration). Colour development was recorded at 405 nm.
Confocal microscopy
MCF-7 cells were grown to ∼80% confluency in 8-well chamber
slides and serum starved for 4 h. Cells were then incubated in the
presence or absence of 100 nM RAP in binding buffer, at 37 ◦C
for 15 min. The cells were then incubated with uPA, uPA–PAI-
1, uPA–PAI-1R76E or uPA–PAI-2 (10 nM) in binding buffer, at
37 ◦C for 30 min. Following two washes with ice-cold PBS, the
cells were fixed with 3.75% (w/v) paraformaldehyde, permeabil-
ized with 0.2% Triton X-100, blocked with 1% BSA/PBS
and probed with anti-phosphotyrosine antibodies (5 µg/ml), for
45 min at 4 ◦C in 1% BSA/PBS. Following a further two washes,
the cells were incubated with anti-mouse IgG-FITC (1:200) and
TO-PRO 3 (1:400) in 1% BSA/PBS for 45 min at 4 ◦C. After
washing, the cells were analysed by confocal microscopy using a
Leica TCS SP system.
Cell proliferation assay
MCF-7 cell proliferation assay was performed using the CellTiter
96® AQueous One Solution Cell Proliferation Assay (Promega)
essentially as described previously [28].
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 1 uPAR and VLDLr mediate the endocytosis of uPA–PAI-2 by MCF-7 cells
MCF-7 cells were probed with 10 µg/ml of primary (A) uPAR, (B) VLDLr or (C) LRP polyclonal antibodies. These were detected using anti-rabbit IgG-FITC (1:50 dilution) and the cells analysed by
flow cytometry, using propidium iodide to exclude non-viable cells. (D) MCF-7 cells were incubated in the presence or absence of RAP (200 nM) for 15 min at 37◦C, prior to analysis of PAI-2–Alexa
Fluor®488 or uPA–PAI-2–Alexa Fluor® 488 internalization using the fluorescence quenching internalization assay (means +− S.E.M., n = 3; *P < 0.05).
Protein structure analysis
Protein structure analysis and Figure preparation was performed
using the PyMol software package (DeLano Scientific). Structural
co-ordinates were obtained from X-ray crystal structures of the
relaxed conformations of both PAI-1 (PDB code 9PAI) [32] and
PAI-2 C–D loop deletion mutant (PDB code 1JRR) [33].
RESULTS
uPA–PAI-2 endocytosis is mediated by uPAR and VLDLr
To confirm the suitability of MCF-7 cells for examining PAI-
2 endocytosis and potential associated signalling events, the
cell-surface expression of uPAR and VLDLr was analysed by
flow cytometry. Both VLDLr and uPAR were detected on the
surface of MCF-7 cells (Figures 1A and 1B). We have previously
shown that LRP mediates PAI-2 endocytosis in PC-3 cells in
an uPA/uPAR dependent manner [19]. However, LRP was not
detected on MCF-7 cells (Figure 1C), confirming previous studies
[25]. As megalin (LRP2) was also not detectable on these cells
(results not shown), we concluded that VLDLr was the only
LDLR family member of relevance on MCF-7 cells. Internal-
ization assays were undertaken to confirm the involvement of
receptor-bound uPA and VLDLr in the endocytosis of PAI-2.
Relatively little PAI-2 internalization was observed in the absence
of exogenous uPA, which was not sensitive to inhibition by RAP, a
specific competitive inhibitor of LDLR binding (Figure 1D). Upon
addition of uPA–PAI-2, significant RAP-sensitive internalization
was observed (Figure 1D), indicating the presence of significant
levels of unoccupied uPAR on these cells and once again
highlighting the uPAR-binding dependency of subsequent uPA–
PAI-2 endocytosis. This process was confirmed to be VLDLr-
dependent, as pre-incubation with 10 µg/ml anti-VLDLr block-
ing antibodies 5F3 or 1H5 [31] caused a similar reduction in uPA–
PAI-2 endocytosis as RAP (results not shown). This data, in the
context of our previous data showing uPA/uPAR dependence [10],
confirm that both uPAR and VLDLr are necessary for uPA–PAI-2
endocytosis in MCF-7 cells.
PAI-2 does not contain a high-affinity binding site for VLDLr
The PAI-1 component of the uPA–PAI-1 complex contains a
cryptic high-affinity binding site for LRP and VLDLr, centered
around the Arg76 residue within helix D [23,24]. We have
previously shown that PAI-2 cannot directly bind LRP, indicating
that it does not contain a similar binding site for LRP [19]. We
utilized SPR analysis to characterize the binding of uPA–PAI-2 to
VLDLr, and compared this with uPA–PAI-1 binding. Significantly
stronger binding of uPA–PAI-1 to VLDLr compared with uPA–
PAI-2 and uPA–PAI-1R76E was observed (Figure 2). Relatively
lower binding of PAI-1 (Figure 2), and no binding of PAI-2 or PAI-
1R76E (results not shown) to VLDLr was detected. uPA proteolytic
activity was not necessary for binding of uPA to VLDLr as no
difference in binding was observed following PMSF inactivation
of uPA (results not shown).
Quantitative analysis showed that PAI-1 binding to VLDLr
best fitted a 1:1 binding model, with a KD of ∼52 nM (Table 1).
uPA and uPA–PAI-1 displayed complicated binding kinetics that
best fitted a model where both uPA and uPA–PAI-1 contain two
separate binding sites of higher and lower affinity capable of
binding to VLDLr independently, but in a competitive manner
(Table 1). The two sites within uPA bound to VLDLr with KD
values of ∼209 and ∼31 nM. The two sites within uPA–PAI-
1 bound to VLDLr with KD values of ∼85 nM and ∼1.5 nM
(Table 1). Binding of uPA–PAI-1R76E or uPA–PAI-2 to VLDLr
c© The Authors Journal compilation c© 2007 Biochemical Society
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Table 1 The kinetics parameters of PAI-1, PAI-1R76E, PAI-2, uPA and uPA–serpin complexes binding to VLDLr, measured by SPR
aBinding data was fitted using the BIAevaluation 4.0 software. The binding model chosen represents that with the lowest φ2 value. Values are means +− S.E.M., n = 3.
Analyte Binding model k a (M−1 · s−1) k d (S−1) K Da (nM) ϕ2
PAI-1 1:1 9.90 × 104 (+− 6.83 × 104) 4.17 × 10−3 (+− 1.19 × 10−3) 51.8 (+− 21.9) 8.12
PAI-1R76E No binding – – – –
PAI-2 No binding – – – –
uPA Heterologous analyte 8.00 × 104 (+− 1.08 × 104) 1.32 × 10−2 (+− 0.01 × 10−2) 209 (+− 25.1) 13.9
5.48 × 104 (+− 0.74 × 105) 1.50 × 10−3 (+− 0.13 × 0−3) 31.2 (+− 5.69)
uPA–PAI-1 Heterologous analyte 1.50 × 105 (+− 0.20 × 105) 1.30 × 10−2 (+− 0.10 × 10−2) 84.8 (+− 1.69) 19.6
1.00 × 105 (+− 0.40 × 104) 1.30 × 10−4 (+− 0.18 × 10−3) 1.51 (+− 0.27)
uPA–PAI-1R76E 1:1 7.79 × 104 (+− 0.84 × 104) 7.08 × 10−4 (+− 2.01 × 10−4) 9.95 (+− 3.53) 8.2
uPA–PAI-2 1:1 1.73 × 105 (+− 0.62 × 105) 5.61 × 10−4 (+− 0.98 × 10−4) 4.68 (+− 0.90) 1.9
Figure 2 SPR (BIAcore) analysis of PAI-1 and PAI-2 binding to VLDLr
Sensorgrams showing the interaction between 100 nM PAI-1 (thin grey line), uPA, uPA–PAI-1,
uPA–PAI-1R76E or uPA–PAI-2 (thick grey line) and immobilized VLDLr. Binding of 100 nM
PAI-1R76E or PAI-2 to VLDLr was not detected (results not shown). The data shown are
representative for at least three independent experiments.
best fitted a 1:1 binding model with a KD of ∼10 and ∼5 nM
respectively (Table 1).
Structural analysis of serpin–VLDLr binding
The Arg76 residue within helix D of PAI-1 is crucial for binding
of PAI-1 and uPA–PAI-1 to LRP or VLDLr [24] (Figure 2).
Although a homologous residue (Arg108) is conserved within helix
D of PAI-2 [34], PAI-2 does not bind VLDLr (Table 1) or LRP
[19] and uPA–PAI-2 binds with much lower affinity than uPA–
PAI-1 (Figure 2). Many ligands interact with members of the
LDLR family via complementary regions of positive electrostatic
potential in the ligand and negative electrostatic potential in the
receptor [35,36]. Therefore the differential binding of uPA–PAI-1
and uPA–PAI-2 to LDLR members may be heavily influenced
by the charge of their respective helix D regions and adjacent
residues.
At physiological pH, PAI-2 carries a relatively negative charge
(predicted pI = 5.4) compared with PAI-1 (predicted pI = 7), as
reflected in the comparative surface electrostatic potentials of
the two molecules in the relaxed conformation (Figures 3E and
3F). Helix D of PAI-1 has a mostly basic (positive) charge,
whereas helix D of PAI-2 is more neutral and surrounded by multi-
ple acidic (negative) regions. Furthermore, Arg76 of PAI-1 is
located in the middle of a basic cavity bounded by Lys80 and
Arg136, whereas the corresponding residue in PAI-2 sits on the
edge of a smaller basic region, with Lys80 being replaced by Ser112
(Figures 3E and 3F). Jensen et al. [37] have proposed a minimal
binding motif in LRP ligands, comprising two basic residues
separated by 2–5 residues and N-terminally flanked by hydro-
phobic residues. A sequence containing both Arg76 and Lys80 in
helix D of PAI-1 fits this motif; however, this sequence is not
conserved in PAI-2 (Figure 3G). Hence, both the electrostatic
environment and surface topography of helix D, particularly
surrounding the Arg76/108 residue, may explain the observed
differences in binding of PAI-1 and PAI-2 to VLDLr and LRP.
Serpin internalization is related to VLDLr affinity
The effect of serpin inhibition and associated complex formation
upon uPA internalization by MCF-7 cells was analysed using
Alexa Fluor® 488-labelled uPA. As previously reported for
PC-3 cells [19], we observed relatively little internalization of
exogenous uPA after 1 h (Figure 4A). However, significantly
increased uPA–PAI-1 internalization (∼8.5-fold) was observed
in the same timeframe (Figure 4A). By comparison, a ∼4–5-fold
increase in uPA–PAI-1R76E or uPA–PAI-2 internalization was
observed compared with uPA alone (Figure 4A). RAP-mediated
inhibition of uPA or uPA–serpin internalization confirmed the
involvement of VLDLr in this process (Figure 4A). Hence, there
was a very strong correlation between the affinity of uPA–serpin
complexes for VLDLr and uPA–serpin internalization by MCF-
7 cells (Figure 4B), indicating that VLDLr affinity may be the
rate-limiting determinant of uPA/uPAR clearance from the cell
surface. Even so, the rate of cell-surface uPA inhibition by
PAI-1 and PAI-2 was very similar over a 30 min incubation period
(Figure 4C).
PAI-2 does not induce mitogenic signalling in MCF-7 cells
The high-affinity VLDLr-binding site in PAI-1 has previously
been implicated in the initiation of signalling events by uPA–
PAI-1 in breast cancer cells [28]. The absence of a correspond-
ing high-affinity site in PAI-2 suggests potential differences in
signalling capacities between these serpins. As a global indicator
of intracellular signalling events [29], we utilized confocal
microscopy to visualize protein tyrosine phosphorylation in
MCF-7 cells after stimulation by uPA, uPA–PAI-1, uPA–PAI-
1R76E and uPA–PAI-2 for 30 min. Stimulation by uPA–PAI-1
induced significant cytoplasmic and nuclear protein tyrosine phos-
phorylation, which was blocked by the addition of RAP (Figure 5).
In stark contrast, protein tyrosine phosphorylation was not
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 3 Comparison of PAI-1 and PAI-2 VLDLr-binding interfaces
(A–D) Ribbon representation showing secondary structure and position of key binding residues within or adjacent to α-helix D of PAI-1 and PAI-2. (E and F) Surface representation showing regions
of positive electrostatic potential in blue, regions of negative potential in red and neutral regions in white. Surface position of helix D and key binding residues within or adjacent to this region
are outlined in yellow. (G) Alignment of helix D amino acid sequence from PAI-1 and PAI-2. The putative minimal binding motif [37] in PAI-1 is underlined with necessary basic and hydrophobic
residues highlighted in yellow and blue respectively. Analysis was performed using PyMol and X-ray crystal structures of the relaxed conformations of both PAI-1 (PDB code 9PAI, [32]) and PAI-2
C–D loop deletion mutant (PDB code 1JRR, [33]).
observed after a 30 min incubation with uPA, uPA–PAI-1R76E or
uPA–PAI-2 (Figure 5).
As uPA–PAI-1 is known to induce the proliferation of MCF-
7 cells [28], we also compared the effect of uPA–PAI-1 with
uPA–PAI-2 on MCF-7 cell proliferation. A ∼60% increase in
proliferation of MCF-7 cells (relative to control) was observed
after 36 h stimulation with uPA–PAI-1 (Figure 6). This effect was
inhibited by RAP, again confirming a VLDLr-mediated effect.
Consistent with the results above showing a lack of general
protein tyrosine phosphorylation, no effect on cell proliferation
was apparent following incubation with uPA, uPA–PAI-1R76E or
uPA–PAI-2 (Figure 6).
DISCUSSION
In the present study we demonstrate that while VLDLr binds and
mediates the endocytosis of uPA–PAI-1 and uPA–PAI-2 on breast
cancer cells, clear structural differences exist which impact upon
the binding mechanisms between these complexes and VLDLr.
As the previously established LRP and VLDLr binding determin-
ants in PAI-1 are absent in PAI-2, these may account for the lack
of downstream signalling events associated with PAI-2 inhib-
ition of uPA. PAI-2 thus appears to mainly result in the in-
hibition and clearance of cell surface uPA, which may potentially
explain why increased PAI-2 expression levels relate to positive
disease outcomes in breast cancer.
PAI-1 can promote invasion and metastasis independent of
its inhibition of uPA-mediated proteolysis. For example, PAI-1
regulates cell migration through vitronectin binding, blocking cell
attachment via uPAR and integrins [38]. Alternatively, uPA–PAI-
1 stimulates pro-proliferative signalling events via a high-affinity
interaction with VLDLr on MCF-7 cells [28], which also mediates
endocytosis of this complex in various cell lines [7]. Given the
lack of LRP expression on MCF-7 cells and the inhibition of uPA–
PAI-2 endocytosis by blocking VLDLr (Figure 1), we undertook
SPR analysis to characterize binding of uPA–PAI-1 and uPA–PAI-
2 to VLDLr. These analyses confirmed a high-affinity interaction
between uPA–PAI-1 and VLDLr. In contrast, we demonstrated
that uPA–PAI-2 binds to VLDLr in a similar manner to uPA–
PAI-1R76E, which lacks the high-affinity binding site in PAI-1 for
VLDLr and LRP [24]. The mutation of Arg76 within helix D of
PAI-1 results in a 10-fold reduction in the ability of uPA–PAI-
1 and trypsin–PAI-1 to compete for binding to LRP [24]. Inter-
estingly, in our studies this mutation also resulted in a complete
abrogation of the binding of uncomplexed PAI-1 to VLDLr.
It should be noted that previous studies of uPA–PAI-1 binding to
VLDLr, using solid-state binding assays, reported a 1:1 interaction
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 4 VLDLr-mediated internalization of uPA–serpin complexes by MCF-7 cells
(A) MCF-7 cells were incubated in the presence or absence of RAP (200 nM) for 15 min at 37◦C, prior to analysis of uPA–Alexa Fluor® 488 internalization using a fluorescence quenching
internalization assay (means +− S.E.M., n = 3). (B) Relationship between the affinity of uPA and uPA–serpin complexes for VLDLr (Table 1, n = 3) and internalization (n = 2). (C) The inhibition
of cell surface uPA activity by PAI-1 and PAI-2. MCF-7 cells pre-incubated with uPA (5 nM) at 4◦C for 30 min were washed and then incubated with PAI-1 or PAI-2 (5 nM) at 37◦C for the time
periods indicated. uPA activity was measured indirectly by the addition of plasminogen (0.5 µM) and Spectrozyme-PL (0.4 mM) for 2 h. Absorbance was read at 405 nm. Activity in the absence of
exogenous uPA was subtracted from all measurements (means +− S.E.M., n = 3).
with KD values of 14 and 15 nM [18,39]. Our SPR analyses of
uPA–PAI-1 binding to VLDLr indicate a more complex interac-
tion. However, if we force-fitted our data to a simple 1:1 inter-
action model, a similar KD of 24 +− 3 nM was obtained, but with
a greatly reduced significance of fit (ϕ2 = 38). Other studies have
reported higher affinity 1:1 binding interactions between uPA–
PAI-1 and VLDLr, with KD values of 0.8, 1.5 and 1.6 nM [40–42].
These values are almost identical with that which we obtained
for the high-affinity VLDLr-binding site in PAI-1 (Table 1).
Although the heterologous analyte model of uPA and uPA–PAI-1
binding to VLDLr does not provide a perfect fit, it is currently
the best available model (lowest ϕ2 values) and suggests that a
1:1 model is not appropriate or accurate. Indeed, the presence
of an independent, moderate-affinity binding site within the uPA
moiety of uPA–PAI-1 (Table 1) has previously been suggested
[24]. Furthermore, another study utilizing SPR to investigate the
binding of uPA–PAI-1 to VLDLr focused on the initial fast-
association and later slow-dissociation phases, while ignoring
the slow-association and fast-dissociation phases, indicative of
a second lower affinity site, present in the data [42]. It could also
be expected that a heterologous analyte model would be observed
for the binding of uPA–PAI-1R76E as only one residue has been
mutated, although it is probable that the disruption of adjacent
residues within this area has significantly altered the biochemistry
of the interaction (as discussed below).
The strong correlation between the affinity of uPA–serpin
complexes for VLDLr, together with its specific involvement
in uPA–PAI-2 internalization by MCF-7 cells, indicates that
VLDLr affinity may be the primary determinant of uPA–serpin/
uPAR internalization in these cells. Comparison of structural
characteristics of PAI-1 and PAI-2 in their relaxed conformations
(i.e. mimicking the conformation in uPA–serpin complexes)
[32,33], provides a clear explanation for the differential binding
of PAI-1 and PAI-2 to VLDLr and LRP (Figure 3). Amino acid
residues Arg76, Lys80 and Lys88 within and adjacent to helix D
of PAI-1 contribute to binding of PAI-1 to LRP [43]. Along
with Arg118 and/or Lys122 (within β-strand 1A), these residues
have also been shown to contribute to the binding of the uPA
complexed form of PAI-1 to LRP and VLDLr [23,43], with
Arg76 forming part of a cryptic high-affinity binding site for LRP
exposed by complex formation with uPA [24]. These residues
conform with the proposed common binding motif for LRP
ligands of two basic residues separated by 2–5 residues and N-
terminally flanked by hydrophobic residues [37]. This motif is
not conserved in PAI-2. Although the residue corresponding to
Arg76 in PAI-1 is conserved within helix D of PAI-2 (Arg108),
the residue corresponding to Lys80 is replaced by a serine residue
(Ser112) in PAI-2 and the adjacent hydrophobic residue is not
conserved (Figure 3). Furthermore, there are clear differences in
the surface topography and overall electrostatic charge between
PAI-1 and PAI-2. Previous studies have shown that mutation of
basic residues within and adjacent to helix D of PAI-1, specifically
the Arg76, Lys80 and Arg118 residues, can reduce affinity of uPA–
PAI-1 for LDLR members [23,42]. This mechanism is further
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 5 uPA–PAI-2 does not induce nuclear/cytoplasmic protein tyrosine
phosphorylation
MCF-7 cells were serum starved for 4 h and incubated in the presence or absence of RAP
(200 nM) for 15 min at 37◦C, then incubated with 10 nM uPA, uPA–PAI-1, uPA–PAI-1R76E or
uPA–PAI-2 for 30 min at 37◦C. The cells were washed with ice-cold PBS, fixed with 3.75 % (w/v)
paraformaldehyde and permeabilized with 0.2 % Triton X-100. After incubation with 10 µg/ml
anti-phosphotyrosine monoclonal antibody (PY20), the cells were washed and incubated with
goat anti-mouse IgG-FITC (1:200 dilution) and TO-PRO 3 (1:400). After washing, the cells were
analysed by confocal microscopy. The scale bar represents 10 µm.
supported by a recent detailed description of the interaction
between RAP domain 3 and LDLR type-A modules highlighting
the importance of electrostatic and hydrophobic interactions
between these binding determinants [35]. As our modelling is
based on the structure of a C–D loop deletion mutant of PAI-2, it
is difficult to predict the influence of the C–D loop on LRP/VLDLr
binding. However, preliminary results suggest that deletion of the
C–D loop does not alter the affinity of uPA–PAI-2 for VLDLr
(results not shown).
uPA–PAI-2 and uPA–PAI-1R76E did not induce the significant
global tyrosine phosphorylation observed following incubation
of MCF-7 cells with uPA–PAI-1 (Figure 5). Furthermore, the
proliferation of MCF-7 cells stimulated by uPA–PAI-1 was not
observed following treatment with either uPA–PAI-2 or uPA–PAI-
1R76E (Figure 6). The mitogenic signalling initiated by uPA–PAI-1
in MCF-7 cells has previously been attributed to the sustained
activation of ERK 1/2 (extracellular-signal-regulated kinase 1/2)
[28]. It was demonstrated that uPA binding to its receptor induces
a transient pulse of ERK phosphorylation, although following
PAI-1 inhibition, uPA–PAI-1 binds to VLDLr, resulting in the
Figure 6 uPA–PAI-2 does not stimulate cell proliferation of MCF-7 cells
MCF-7 cells were cultured in RPMI/5 % (v/v) fetal calf serum for 48 h, then treated with 10 nM
uPA, uPA–PAI-1, uPA–PAI-1 plus RAP (200 nM), uPA–PAI-1R76E, uPA–PAI-2 or vehicle in RPMI
containing 300 µg/ml glutamine, 5 µg/ml transferrin and 38 nM selenium. After culturing for
36 h, cell growth was determined using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Values of cell proliferation are
relative to the proliferation of control cells (i.e. vehicle only). (means +− S.E.M., n = 6,
*P < 0.05).
sustained activation of ERK [28]. The putative mechanisms
of VLDLr-mediated cell signalling induced by uPA–PAI-1 are
discussed in detail by Strickland et al. [7]. However, given the
striking differences in binding mechanisms described above, these
results suggest that the lack of a high-affinity VLDLr-binding
site in PAI-2 prevents the initiation of these mitogenic signalling
events. Indeed, we do not observe any additional ERK activation
by uPA–PAI-2 over and above the transient activation initiated by
uPA alone binding to uPAR on MCF-7 cells (results not shown).
Clearly, PAI-1 and PAI-2 have differential effects on uPA/uPAR
endocytosis and mitogenic signalling. Although both PAI-1
and PAI-2 inhibit cell surface uPA and consequently decrease
pericellular plasminogen activation capacity, PAI-1 has significant
additional functional roles stimulating cell proliferation. We now
propose a novel structural mechanism for this functional dif-
ference based on the absence of a high-affinity LDLR-binding site
in PAI-2. Thus the poor prognosis for breast cancer patients with
high uPA/PAI-1 protein levels may be associated with the ability
of PAI-1 to initiate mitogenic signalling events through LDLRs
such as VLDLr. In contrast, the favourable overall survival of
patients with high PAI-2 protein expression may be due to uPA
inhibition and clearance via LDLRs without the cell signalling
events and increased metastatic potential associated with high
PAI-1.
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